ReviewFrontiers in cardiovascular medicine2026
Atrial fibrillation and metabolic syndrome: an updated review of mechanisms, risk factors, and therapeutic strategies.
Review in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, atrial fibrillation (AF) has emerged as one of the most prevalent cardiac arrhythmias with escalating global incidence. Characterized by complex pathophysiology and unfavorable clinical outcomes, AF has become a focal point in cardiovascular research. Concurrently, metabolic syndrome (MetS)-a clinical constellation encompassing obesity, insulin resistance or impaired glucose metabolism, hypertension, and dyslipidemia-has evolved into a major global public health challenge. Accumulating clinical evidence indicates that MetS confers a 1.5-2 times increased risk of AF development compared with the general population, underscoring intricate pathophysiological interconnections between these conditions. Although conventional perspectives attribute this association primarily to obesity and hypertension, emerging research implicates multifactorial mechanisms including myocardial fibrosis, atrial electrical-structural remodeling, systemic inflammation, oxidative stress, adipokine dysregulation, and autonomic nervous system dysfunction. Nevertheless, the association of MetS with AF remains incompletely understood, with ongoing debates regarding the independent contributions and synergistic interactions of individual metabolic components in modifying atrial substrate. This review synthesizes current epidemiological evidence, explores the molecular mechanisms of the MetS and AF interfaces, and evaluates recent advances in clinical intervention strategies, with the aim of informing early preventive approaches and precision therapeutics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.